DEVELOPMENT AND IN VITRO - IN VIVO EVALUATION OF OCULAR INSERT CONTAINING KETOROLAC TROMETHAMINE AND MOXIFLOXACIN HYDROCHLORIDE.

Conjunctivitis is a common eye disorder that causes swelling and inflammation of the conjunctiva.  Topical dosage form containing antibiotics and non-steroidal anti-inflammatory drugs are prescribed for the treatment and in order to overcome problems of conventional dosage forms the present study aims to develop an ocular insert containing Moxifloxacin HCl and Ketorolac Tromethamine. Insert was prepared by a solvent casting method by taking different polymers PVA, PVP K 30, and a combination of both as film-forming polymer, and glycerol as a plasticizer and characterized by various parameters like thickness, folding endurance, pH, swelling index, drug content, mechanical properties, in vitro and in-vivo release study. The Formulation prepared by a combination of both polymers demonstrated significantly improved properties including % Elongation, tensile strength, swelling index, drug content and drug release compared to the formulation made with single polymer. The In vitro release data indicated that the batch R8 exhibited sustain release of drug (85 % release in 10 hr) and following the Higuchi model for release kinetics. In vivo, study in rabbit eyes revealed the sustained release of the drug up to 16 hr with a good correlation between in vitro and in vivo release data. From the study, it can be concluded that the developed ocular insert can be a promising formulation for rational therapy of conjunctivitis.

Informations de copyright

Copyright © 2024 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.